Cabotres — Cabozantinib
Cabozantinib is a multi-kinase inhibitor that gives oncologists an oral, targeted-therapy option across three genuinely distinct cancer types treated by the same drug — kidney, liver, and thyroid cancer — which makes it a versatile addition for hospitals managing patients across multiple oncology sub-specialties rather than a single-indication product.
- Approved indications: Renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), differentiated thyroid cancer
- Mechanism: Inhibits multiple tyrosine kinases (including MET, VEGFR2, and RET) simultaneously, blocking several tumor-growth and blood-vessel-formation pathways at once
- Administration: Oral tablet, once daily
- Oral advantage: Provides a targeted-therapy alternative to the injectable oncology biologics in our catalogue treating the same cancer types, relevant for distributors serving facilities without infusion infrastructure
Key Product Facts
20 mg, 40 mg, 60 mg
Strength
30 Tablet (S) In A Bottle
Pack Size
Cabozantinib
Active Ingredient
Oncology
Category
Enquire Now for Pricing
Price
Cabozantinib is a multi-kinase inhibitor that gives oncologists an oral, targeted-therapy option across three genuinely distinct cancer types treated by the same drug — kidney, liver, and thyroid cancer — which makes it a versatile addition for hospitals managing patients across multiple oncology sub-specialties rather than a single-indication product.
- Approved indications: Renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), differentiated thyroid cancer
- Mechanism: Inhibits multiple tyrosine kinases (including MET, VEGFR2, and RET) simultaneously, blocking several tumor-growth and blood-vessel-formation pathways at once
- Administration: Oral tablet, once daily
- Oral advantage: Provides a targeted-therapy alternative to the injectable oncology biologics in our catalogue treating the same cancer types, relevant for distributors serving facilities without infusion infrastructure
- Hemorrhage risk: Significant bleeding risk requires careful patient selection and monitoring, particularly in patients with a bleeding history
- GI perforation risk: A rare but serious risk requiring immediate medical attention if abdominal symptoms develop
- Hypertension: Common and requires regular blood pressure monitoring
- Wound-healing complications: Treatment should be held before and after any planned surgery, similar to the precaution with Bevacizumab
- Hepatotoxicity: Regular liver function monitoring recommended
- Pregnancy: Contraindicated
| Document |
Included |
| Certificate of Analysis (COA) |
Standard |
| Certificate of Origin (COO) |
Standard |
| MSDS |
Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: Standard export logistics, no cold chain required
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Cabozantinib used for?
Treats kidney cancer, liver cancer, and differentiated thyroid cancer.
Get Cabozantinib price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Is it chemotherapy?
No, it's a targeted oral therapy that blocks multiple cancer-growth pathways simultaneously.
Does it need to be stopped before surgery?
Yes, similar to other anti-angiogenic drugs, it should be held before and after any planned surgery due to wound-healing risk.
Who supplies Cabozantinib from India?
WHO-GMP certified tablet manufacturing with full export documentation.
